Skip to main content
HANGZHOU AGS MEDTECH CO.,LTD logo

HANGZHOU AGS MEDTECH CO.,LTD — Investor Relations & Filings

Ticker · 688581 ISIN · CNE100005ZF0 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 393 across all filing types
Latest filing 2024-05-13 Capital/Financing Update
Country CN China
Listing Shanghai Stock Exchange 688581

About HANGZHOU AGS MEDTECH CO.,LTD

http://www.bioags.com/en/index.aspx

Hangzhou AGS MedTech Co., Ltd. specializes in the research, development, and manufacturing of minimally invasive medical instruments, primarily focusing on endoscopic accessories. The product portfolio encompasses a comprehensive range of disposable devices for gastrointestinal and respiratory interventions, including biopsy forceps, hemoclips, injection needles, polypectomy snares, and guide wires. The company integrates advanced manufacturing processes with rigorous quality management systems, adhering to international standards such as ISO 13485, CE, and FDA. By providing high-precision diagnostic and therapeutic tools, the organization supports clinical procedures in gastroenterology and pulmonology. Its technical expertise facilitates the delivery of reliable solutions aimed at improving procedural outcomes and patient safety in global healthcare markets.

Recent filings

Filing Released Lang Actions
安杰思关于使用闲置自有资金进行现金管理的公告
Capital/Financing Update Classification · 95% confidence The document is a public announcement by Hangzhou Anjiesi Medical Technology Co., Ltd. regarding the use of idle self-owned funds for cash management. It details the investment purpose, amount, types of investment products, risk control measures, and approvals by the board and supervisory committee. The document is an announcement of a financing or capital management activity, specifically about the company's plan to invest idle funds in low-risk financial products. It is not a full financial report, audit, or earnings release, nor is it a regulatory filing or certification. The content fits best under Capital/Financing Update (CAP) as it updates on the company's financing activities and capital management plans. The document length is short and it is not a report publication announcement or certification. Therefore, the classification is CAP with high confidence.
2024-05-13 Chinese
中信证券股份有限公司关于杭州安杰思医学科技股份有限公司增加使用部分暂时闲置募集资金进行现金管理额度的核查意见
Regulatory Filings Classification · 95% confidence The document is a detailed verification opinion from the sponsor (中信证券股份有限公司) regarding the increase in the quota for using temporarily idle raised funds for cash management by 杭州安杰思医学科技股份有限公司. It includes detailed descriptions of the raised funds, investment projects, cash management purposes, limits, products, risk controls, and approvals by the board and supervisory committee. The document references regulatory rules and approvals but does not contain financial statements or quarterly/yearly financial results. It is a formal verification and opinion report related to the use of raised funds, not an annual or interim financial report, earnings release, or capital update. It is not a simple announcement or certification but a substantive report on a specific regulatory compliance matter related to cash management of raised funds. This fits best under the category of Regulatory Filings (RNS), which covers general regulatory announcements and compliance documents that do not fit other specific categories.
2024-05-13 Chinese
中信证券股份有限公司关于杭州安杰思医学科技股份有限公司首次公开发行部分限售股及部分战略配售股上市流通的核查意见
Regulatory Filings Classification · 95% confidence The document is a detailed verification opinion from CITIC Securities regarding the listing and circulation of certain restricted shares and strategic placement shares of Hangzhou Anjiesi Medical Technology Co., Ltd. after its initial public offering (IPO) on the STAR Market. It discusses the types and quantities of restricted shares, lock-up periods, shareholder commitments, and compliance with regulatory requirements. The document is not an announcement of a report publication but a substantive verification opinion related to share circulation post-IPO. This type of document aligns with regulatory filings related to share issuance and capital changes but is not a direct announcement of new shares or capital changes itself. It is a formal verification opinion by the sponsor on share circulation compliance. Given the content and nature, the best fitting category is Regulatory Filings (RNS), as it does not fit neatly into other categories like Share Issue/Capital Change (SHA) or Capital/Financing Update (CAP) which typically involve announcements of new share issues or financing activities rather than verification opinions. The document length is 3611 characters, which is relatively short but contains substantive content, not just a brief announcement or certification. Therefore, classification as RNS is appropriate with high confidence.
2024-05-09 Chinese
安杰思首次公开发行部分限售股及部分战略配售股上市流通公告
Regulatory Filings Classification · 95% confidence The document is an official announcement from Hangzhou Anjiesi Medical Technology Co., Ltd. regarding the listing and circulation of certain restricted shares and strategic placement shares following the company's initial public offering (IPO). It details the number of shares, lock-up periods, shareholder commitments, and the date when these shares will become tradable. The document references regulatory approval from the China Securities Regulatory Commission and compliance with Shanghai Stock Exchange rules. The content is focused on the release of restricted shares into the market rather than financial results, management changes, or other report types. The document length is 3505 characters, which is relatively short and consistent with an announcement rather than a full report. Therefore, this fits the category of a Regulatory Filing (RNS) as it is a regulatory announcement about share listing and circulation, not a full financial report or other specific filing type.
2024-05-09 Chinese
安杰思关于召开2023年度暨2024年第一季度业绩说明会的公告
Regulatory Filings Classification · 95% confidence The document is an announcement from Hangzhou Anjiesi Medical Technology Co., Ltd. about the scheduling of an investor performance briefing for the 2023 annual and 2024 first quarter results. It specifies the date, time, location, and format of the meeting, and invites investors to participate and submit questions. The document references that the 2023 annual report and 2024 first quarter report have already been published on April 23, 2024, but this document itself does not contain any financial data or detailed results. It is clearly an announcement about an upcoming earnings call or performance explanation meeting rather than the transcript or the report itself. Given the nature of the document as a notice for an earnings results explanation meeting, the most appropriate classification is Call Transcript (CT) since it is about a performance briefing, but since it is only an announcement of the meeting and not the transcript itself, it fits best under Regulatory Filings (RNS) as a general regulatory announcement. However, the document is specifically about an earnings explanation meeting, which aligns with the category of Call Transcript (CT) if it were the transcript. But since it is only the announcement, and the document length is short (1559 characters), it is not the transcript itself. According to the rules, announcements of meetings are classified as Regulatory Filings (RNS). Therefore, the correct classification is Regulatory Filings (RNS) with high confidence.
2024-05-06 Chinese
安杰思关于以集中竞价交易方式回购公司股份的进展公告
Transaction in Own Shares Classification · 100% confidence The document is a progress announcement regarding the company's share repurchase program. It details the number of shares repurchased, the price range, total amount spent, and compliance with relevant regulations. It references previous announcements about the repurchase plan and provides updates on the repurchase progress as of specific dates. The document is relatively short (1469 characters) and focuses on the ongoing share buyback activity rather than a full financial report or other types of filings. Therefore, it fits the category of a Transaction in Own Shares (POS) filing, which covers reports of the company buying back its own shares.
2024-05-06 Chinese

Browse filings by year

4 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.